• MPO, via its catalytic activity, inhibits the generation of adaptive immunity by suppressing DC function.
Introduction
Myeloperoxidase (MPO) is an enzyme found in azurophilic granules of neutrophils. 1 It is the major neutrophil protein, accounting for about 5% of the dry cell weight. 1 MPO is also found to a much lesser extent in monocytes and some macrophages. [1] [2] In the presence of hydrogen peroxide (H 2 O 2 ) and a halide (chloride [Cl] , bromide [Br] , thiocyanate [SCN]), tyrosine or nitric oxide (NO), MPO catalyses the formation of powerful reactive intermediates including hypochlorous (HOCl), hypobromous (HOBr) and hypothiocyanous (HOSCN) acids, tyrosyl radical and reactive nitrogen species, respectively, which can have profound biological effects by modifying proteins, lipids and/or DNA. [1] [2] MPO plays an important role in intracellular pathogen killing, but, when released extracellularly following neutrophil activation, can cause tissue damage at inflammatory sites, as demonstrated in patients with immune and inflammatory diseases including cardiovascular disease, rheumatoid arthritis (RA), atherosclerosis, kidney disease, cystic fibrosis and multiple sclerosis (MS). [1] [2] Studies in models of cardiovascular, renal and lung disease [3] [4] [5] also demonstrate that MPO is a local mediator of tissue injury. These studies have implicated MPO as an important therapeutic target, leading to great interest to design MPO inhibitors for the treatment of inflammatory diseases.
However, very little is known about the effects of MPO on adaptive immunity and T cell-driven diseases. Additionaly, the mechanisms by which MPO affects adaptive immune responses are unknown.
Neutrophils, the principal source of MPO, have long been considered solely as first responders in innate immunity. However, increasing evidence suggests that they also influence the development of adaptive immune responses. 6 Neutrophils interact with dendritic cells (DCs) at inflammatory sites 7 and secrete mediators which promote DC maturation. [8] [9] In addition to infiltrating inflamed tissue, neutrophils migrate to draining lymph nodes (LNs) following antigen injection or infection. [10] [11] However, it is not very clear how neutrophils in LNs affect adaptive For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From immunity. Moreover, although neutrophils contain molecules such as NO 12 which regulate effector T cells at inflammatory sites, and can, by unknown pathways, suppress the induction of T cell responses, 13 the mechanisms by which neutrophils may dampen adaptive immunity are poorly understood.
In these studies, the generation of CD4+ T cell responses in LNs was enhanced by MPO deletion or in vivo inhibition, resulting in exacerbated dermal delayed type hypersensitivity (DTH) and antigen (Ag)-induced arthritis (AIA). We hypothesized that MPO attenuates the initiation of T cell responses by affecting DCs. This study shows that MPO is deposited by neutrophils in LNs where it interacts with DCs during the induction of adaptive immunity. We demonstrate that MPO, via enzymatically-dependent formation of reactive intermediates, inhibits the generation of adaptive immune responses by limiting DC activation, Ag uptake/processing and migration to LNs.
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Flow cytometry and confocal microscopy
Proliferation, apoptosis and T and B cell activation, were assessed by intracellular bromodeoxyuridine (BrdU) incorporation (or Ki-67 staining [anti-Ki-67/FITC, clone 35 ; BD]), Annexin-V staining and expression of CD44 and CD69, respectively. 5 Regulatory T cells (Tregs) were identified as foxp3+CD25+CD4+ cells. 17 Mouse DCs were stained with anti-CD11c/PE (BD), anti-CD86/APC-Cy7 (Biolegend), anti-CD40/FITC (BD), anti-CCR7/APC (eBioscience) and anti-MHC-II/APC (Biolegend). Human DCs were stained with anti-CD1a/APC (BD), anti-CD14/PE (Miltenyi), anti-CD86/APC (BD) and anti-HLA-DR FITC (Biolegend). Murine neutrophils were identified as CD11b hi CD11c -MHC-II neg side-scatter hi cells that were Ly-6G + or Gr-1 hi using anti-CD11b/APC-Cy7 (BD), anti-CD11c/PE, anti-MHC-II/APC, anti-Ly-6G/PE (1A8; BD) and anti-Gr-1/Alexa647 (RB6-8C5; DNAX). For CD68 expression, cells were surface-stained with anti-CD68/FITC (FA/11; Biolegend). Flow cytometry was performed using the MoFlo flow cytometer (Summit software; Dako). Frozen LN sections were stained with anti-Ly6G/PE (BD), anti-CD11c/APC (BD) and anti-MPO/FITC (Thermo-Scientific) and analysed by confocal microscopy.
Cytokines, DTH, serum antibody and MPO activity
Mouse cytokines were measured by ELISA. 17 Intracellular cytokine staining was performed as published. 18 Human IL-12p70 was assessed by ELISA using anti-human IL-12p70 (BD), biotin anti-human IL-12p40 (Biolegend) and recombinant human IL-12p70 (BD). DTH was assessed by measuring thickness of footpads injected with OVA or BSA. 5 Serum antibodies were measured by ELISA, 5 using OVA-coated plates. MPO activity was measured as published. 5
In vitro experiments
Murine bone marrow (BM)-derived DCs were generated as described. 8 Non-adherent cells (d8) were enriched for DCs (MoFlo XDP cell sorter, Beckman Coulter; >99% CD11c hi ). 
Cell transfer experiments
CD4-enriched CFSE-labelled naive OT-II cells (Vα2+Vβ5+; OVA 323-339 -specific) were transferred intravenously (i.v.; 3×10 6 /mouse) to mice, as described. 18 
Experiments with human cells
Venous blood from healthy volunteers was centrifuged over Polymorphprep (Axis-Shield, Norway) to obtain PBMCs and neutrophils. PBMCs were enriched (anti-CD14-microbeads;
(Miltenyi) to obtain CD14+ monocytes (>90% purity), which were cultured with recombinant human GM-CSF (800U/ml; R&D Systems) and IL-4 (500U/ml; R&D Systems). On d6, cells were >95% CD1a+ (DCs) and <1% CD14+. Neutrophils (>98% pure; cytospin DIFF-Quik) were incubated with human GM-CSF (1000U/ml; 1h), then fMLP (10μM; 1h) 22 ± ABAH (100μM) or catalase (2000U/ml; Sigma) and supernatant collected. DCs were cultured (24h) with LPS (1μg/ml)/H 2 O 2 (100μM) and with/without human neutrophil supernatant or purified human MPO (Sigma).
Statistics
Results are expressed as mean ± SEM. Unpaired t test and one-way ANOVA (with Bonferroni or Dunnett's test) were used to compare means between 2 or >2 groups, respectively.
Statistical analysis was performed using GraphPad Prism (GraphPad Software). Significance was indicated by P < 0.05.
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Results

MPO suppresses the generation of adaptive immune responses
MPO deficiency increased CD4+ T cell activation and proliferation in LNs and spleen 6d
after OVA/CFA injection ( Figure 1A-B ). T cell activation/proliferation was not different between non-immunised WT and Mpo -/mice (Supplementary Table 1 ). T cell apoptosis and Tregs were not affected by MPO deletion (Supplementary Table 2 ). OVA-stimulated splenocytes from Mpo -/mice secreted more IFN-γ and IL-17A ( Figure 1C ), as well as IL-4 (1.6±0.2 versus 11.3±1.7 pg/ml; (Figure 1Gii ,iii) were also increased in Mpo -/mice. Table 3 ) without reducing their apoptosis (not shown).
MPO deficiency enhanced B cell responses (Supplementary
MPO attenuates AIA
To assess how MPO affects T cell-driven pathological tissue inflammation, we induced AIA in WT and Mpo -/mice. Mpo -/mice had increased CD4+ T cell activation (9.4±1.1 versus 15.7±1.1 % CD44 hi T cells; P<0.01) and IFN-γ production (1778±715 versus 6570±1482 pg/ml; P<0.05) in response to mBSA. In correlation with enhanced arthritogenic T cell immunity, arthritis severity was augmented by MPO deletion (Figure 1Fi ,ii). Similar results were obtained in OVA-induced AIA ( Supplementary Figure 3 ).
Neutrophil MPO interacts with DCs in LNs
Neutrophil infiltration was increased in draining, but not non-draining, LNs after OVA/LPS injection, peaking at 4h and decreasing thereafter ( Figure 2A ). Correlating with neutrophil accumulation, MPO activity was increased in draining LNs at 4h ( Figure 2B ). Neutrophil recruitment in draining LNs before or 4h after OVA/LPS immunisation was not affected by MPO deficiency (0h: 0.06±0.01 versus 0.06±0.03; 4h: 0.51±0.03 versus 0.56±0.04 % neutrophils).
Numerous contacts were observed between neutrophils and DCs in LNs at 4h ( Figure 2C ). Importantly, MPO was detected not only inside, but also outside of neutrophils, and multiple contacts were observed between extracellular MPO and DCs ( Figure 2C ). Figure 4 ). However, at the time when extracellular MPO was detected in LNs (4h), only 0.6% of all LN-infiltrating neutrophils were apoptotic, compared with 5% in normal LNs (Figure 2Ei ). The total number of apoptotic neutrophils was reduced at 4h ( Figure 2Eii ). Similar to previous reports, 11 increased neutrophil apoptosis was observed later on, at 18h (6.4±0.9 % and 23.8±6.1×10 2 total apoptotic neutrophils), correlating with neutrophil disappearance from LNs by 24h.
Neutrophils deposit MPO in LNs via primary granule release
We examined if DCs augment MPO release by neutrophils because neutrophil-DC contacts occured in LNs. Addition of DCs to neutrophil cultures increased MPO levels in cell supernatants ( Figure 2F ), indicating and confirming 23 that DCs enhance MPO release by neutrophils.
MPO suppresses DC activation in vitro through its catalytic activity
To examine if MPO affects DC activation, we first performed in vitro experiments. WT and Mpo -/neutrophils were degranulated in the presence or absence of the MPO inhibitor (ABAH) to be able to test if MPO-mediated effects on DCs are dependent on its catalytic activity. Enzymaticallyactive MPO in supernatant from CB/fMLP-stimulated WT neutrophils was inhibited by ABAH and was undetectable in Mpo -/supernatant (Supplementary Table 4 ). In the presence of H 2 O 2 (essential MPO substrate), WT supernatant dose-dependently inhibited LPS-induced DC activation ( Figure   3A ). WT supernatant containing ABAH and Mpo -/supernatant reversed this effect, completely at lower and partially at higher supernatant doses. ABAH in Mpo -/supernatant did not affect DC activation ( Figure 3A ), confirming its specificity. These effects of MPO were not due to increased DC apoptosis (not shown). IL-12 and IL-23 were undetectable in neutrophil supernatants (not shown), indicating that the cytokines measured in DC/neutrophil-supernatant cultures were DCderived. Additionally, purified enzymatically-active mouse MPO dose-dependently suppressed DC activation, effects that were lost when MPO was inhibited by ABAH ( Figure 3B ).
MPO-mediated suppression of DC activation inhibits immune responses in vivo
To show that MPO suppresses adaptive immunity via DCs, we transferred OVA 323-339 - Figure 3C ).
MPO suppresses DC activation through various reactive intermediates
To examine how different MPO-generated oxidants affect DC activation, we cultured DCs with MPO in the presence of various halides. Compared to Cl alone, MPO-mediated inhibition of DC activation was enhanced in the presence of Cl+Br and, to a lesser extent, Cl+SCN ( Figure   4Ai ,ii). Br or SCN did not affect DC activation in the absence of MPO (not shown).
Since MPO can consume NO, 2 we tested the effect of MPO on DCs in the presence or absence of the NO donor, SNP. SNP did not affect DC CD86 upregulation in the absence of MPO ( Figure 4Bi ). Compared to Cl alone, MPO-mediated inhibition of CD86 expression was not affected in the presence of Cl+SNP (Figure 4Bii ). However, SNP reduced DC IL-12 production in the absence of MPO, and MPO-mediated suppression of IL-12 production that occurred in the presence of Cl alone was completely lost when SNP was also present ( Figure 4Biii ). 24 To determine if some MPO-mediated effects were due to H 2 O 2 consumption by MPO, we tested the influence of increasing doses of H 2 O 2 on DC activation, but H 2 O 2 did not alter DC maturation ( Figure 4C ).
Mac-1 is involved in MPO-mediated inhibition of DC activation
To examine if DC Mac-1 is involved in MPO-mediated regulation of DC activation, we tested the effect of MPO on DCs in the presence or absence of anti-Mac-1 antibody (5C6). 5C6 blocks leukocyte adhesion via Mac-1, 21 but affects DC activation in a similar manner as anti-Mac-1 (M1/70) which ligates/activates DC Mac-1 25 (Supplementary Figure 5 ). 5C6 did not affect DC CD86 expression in the absence of MPO, and MPO-mediated inhibition of CD86 expression was not affected by 5C6 ( Figure 4Di ). However, 5C6 downregulated DC IL-12 production in the absence of MPO ( Figure 4Dii ). MPO suppressed DC IL-12 production in the absence, but not in the presence, of the ligating anti-Mac-1 antibody (Figure 4Dii ). Table 5 ).
MPO decreases DC activation in vivo
In correlation with increased DC activation in LNs, T cell responses were enhanced by in vivo administration of ABAH ( Figure 5C ). ABAH did not affect DCs or T cells in Mpo -/mice, indicating its specificity (Supplementary Table 6 ).
MPO inhibits DC migration to LNs
MPO deficiency or in vivo inhibition by ABAH augmented the frequency of endogenous DCs in LNs 18h after OVA/LPS or OVA/CFA injection ( Figure 6A ). The percentage of DCs in LNs of non-immunised Mpo -/mice was decreased (Supplementary Table 5 ). ABAH did not affect the proportion of DCs in LNs of Mpo -/mice (Supplementary Table 6 ).
MPO may suppress DC accumulation in LNs by reducing their survival and/or migration. Table 7 ). However, increased numbers of transferred DCs migrated to LNs of Mpo -/mice ( Figure 6B ). In vitro, WT, but not Mpo -/-, neutrophil supernatant decreased LPS-induced CCR7 upregulation by DCs (Figure 6Ci ).
DC apoptosis in LNs was not affected by MPO deficiency (Supplementary
Additionally, purified mouse MPO dose-dependently reduced DC CCR7 expression ( Figure   6Cii ,iii).
MPO suppresses DC antigen uptake/processing
Culture of DCs with DQ-OVA (which exibits green fluorescence upon proteolytic degradation) showed that MPO suppressed DQ-OVA uptake/processing by DCs in vitro ( Figure   6Di ,ii). In vivo, MPO deficiency increased DQ-OVA uptake/processing by DCs in LNs ( Figure   6Ei ,ii).
MPO from human neutrophils inhibits the activation of human DCs
Human neutrophils were degranulated in the presence or absence of ABAH or catalase Figure 7B ). These effects of MPO were not due to increased DC death (not shown).
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Discussion MPO, the major neutrophil protein, is implicated as a local mediator of inflammatory injury in many chronic human diseases, making it an important therapeutic target. [1] [2] The current studies demonstrate that MPO diminishes the induction of adaptive immunity by inhibiting DCs, to attenuate tissue inflammation. These results add to the complexity of the roles played by MPO in health and disease, detracting from the simplistic view that MPO acts solely as an injurious molecule in inflammatory conditions. Our data also support the growing recognition of a complex interaction between innate and adaptive immunity, providing new insights into how LN-infiltrating neutrophils shape the adaptive immune response and the mechanisms by which neutrophil products limit DC maturation and consequent induction of injurious T cell responses. They define MPO as a regulator of DC activation to prevent the generation of over-exuberant T cell immunity.
Here, enhanced generation of T cell responses due to MPO deletion, supported by observations in experimental glomerulonephritis and MS, 5, 27 resulted in exacerbated AIA, a T celldriven model of RA, 28 indicating that any potential benefit of MPO absence in the joint was overridden by enhanced arthritogenic immunity in secondary lymphoid organs. Augmentation of joint inflammation in Mpo -/mice was supported by increased skin DTH, demonstrating that MPOmediated suppressive effects on the induction of T cell responses cause less tissue inflammation.
We hypothesized that MPO suppresses adaptive immunity by inhibiting DC function since neutrophils, the major MPO source, interact with and affect DCs. 8-10 Here, consistent with previous reports, [10] [11] 13 , neutrophils rapidly and transiently infiltrated draining LNs after OVA/LPS injection.
Although it is possible that some of these cells are immature granulocytic myeloid-derived suppressor cells (because they are also CD11b+Ly-6G+) 29 which may, therefore, contribute to MPO-mediated effects on DCs, they displayed standard features of mature neutrophils including high Ly-6G expression and granularity (side-scatter hi ). Confocal microscopy demonstrated the presence of intracellular and extracellular MPO in LNs at the peak of neutrophil infiltration (4h [41] [42] in other cells. Therefore, they may downregulate DC maturation by modulating signalling pathways and/or surface receptors involved in DC activation.
MPO can also consume NO 2 which itself can attenuate DC activation. 43 Here, DC CD86 expression was NO-independent. However, exogenous NO itself decreased DC IL-12 production, as reported, 43 and MPO-mediated suppression of IL-12 expression in the presence of Cl alone was completely lost when SNP was also present. This suggests that, in vitro, the inhibitory effects of MPO-HOCl on DC IL-12 production are counter-balanced by MPO-mediated consumption of NO.
These results, together with our animal data showing increased DC costimulatory molecule expression and IL-12 production due to MPO deletion or inhibition, suggest that, in vivo, MPO- This suggests an interaction between the MPO-HOCl and Mac-1 pathways in DC IL-12 production.
The nature of this interaction is unknown, but since Mac-1 can be activated not only by ligand binding, but also by free radicals, 47 it is possible that MPO-derived oxidants activate DC Mac-1 (an effect which is bypassed by antibody-mediated Mac-1 activation) thus reducing IL-12 production.
In addition to DC maturation, full induction of T cell responses requires DC Ag uptake/processing and migration to LNs. DQ-OVA studies showed that MPO regulates Ag uptake/processing by DCs. While the mechanisms for this are unknown, it is possible that MPO-HOCl inactivate the DC mannose receptor (which is involved in OVA uptake) and/or proteins involved in Ag digestion. [48] [49] We also showed that MPO limits DC migration to LNs after immunisation by reducing their CCR7 expression. Since MPO oxidants can inactivate chemotactic factors, 50 neutrophil deposition of MPO in LNs may also inactivate LN DC-attracting chemokines.
In summary, we have demonstrated that MPO deposited by neutrophils in LNs interacts with DCs in vivo during the generation of adaptive immunity. MPO, via enzymatically-generated reactive intermediates, attenuates adaptive immunity by suppressing murine (and human) DC activation, antigen uptake/processing and migration to LNs, resulting in decreased pathological tissue inflammation. These findings, supported by observational studies in patients with genetic deficiency or decreased expression of MPO, [33] [34] [35] [36] [37] provide cautionary information when considering MPO as a therapeutic target. 
Figure 7
